Cryotherapy has gained importance as a locally ablative treatment option for patients with non-resectable liver tumors, especially metastases from colorectal cancer. We have used this technique since 1996 for the treatment of 77 patients with malignant liver tumors.
Introduction
Colorectal cancer is among the top three diagnoses for cancer related death in most western countries (1). Liver metastases are present in 15-25% of patients at time of diagnosis of colorectal cancer and another 20% of patients will develop liver metastases following resection of the primary tumor (2). The median survival of patients with liver metastases from colorectal cancer receiving no treatment is less than one year (2), and even with improving results of systemic chemotherapy over the last five years, there are very few long term survivors (3) (4) (5) . Liver resection has been shown to be a safe procedure with a perioperative mortality of less than five per cent and acceptable morbidity and can achieve 5-year survival rates of 20-50% and possible cure in some patients (2, 6, 7) . However, resection is only feasible in a small proportion of patients (7) and hepatic cryotherapy may be a useful treatment option in a proportion of the remaining group of patients with unresectable metastases confined to the liver.
Patients with primary liver cancer often suffer from cirrhosis of the remaining liver. Liver resection in this group of patient may result in inadequate remaining functional liver tissue and liver failure (8), especially in patients with Child B and C cirrhosis. Cryotherapy may provide a method of focal destruction of cancerous tissue with preservation of most of the remaining liver (8).
Material and Methods

Patient Selection -Indications for Hepatic Cryotherapy
While the use of cryotherapy has been reported for many different primary and secondary liver tumors, a large experience exists only for the treatment of hepatocellular carcinoma and metastases from neuroendocrine or colorectal origin (9) (10) (11) (12) (13) .
For primary and secondary liver tumors, we have used liver resection as preferred treatment option whenever possible (Fig. 1 ). Since 1996, we have used cryotherapy if complete resection of all liver tumors was not feasible and if no extrahepatic disease was diagnosed preoperatively.
There were basically four situations where we have used hepatic cryotherapy:
I)
Multiple bilobar tumors, where cryotherapy allows focal destruction of the tumors and preservation of functional liver tissue. While some centers are not treating patients with more than 3 tumors (11, 14) , other centers are very aggressive and treat up to 12 (10) or even 30 lesions (15) in a single patient. Since we were cautious not to produce cryoshock by extended freezing, our goal usually was to resect as many lesions as possible and use resection of the liver lobe with the greater tumor load and cryotherapy of contralateral remaining lesions (10, 16) ( Fig. 2) .
II)
Proximity to major intrahepatic vessels, where cryotherapy may still allow destruction of the tumor without injury to the vessel; as suggested by Gage et al. as early as 1967 , when they demonstrated the resistance of large blood vessels to freezing in a dog model (17) . This is mainly applicable to lesions close to the inferior vena cava (IVC) or hepatic veins (Fig. 3 ). III) Involved or inadequate margin following liver resection. In this situation, cryotherapy of the resection edge might be able to prevent or reduce edge recurrence (8, 16, (18) (19) (20) . IV) Finally, cryotherapy might be useful in patients where tumors would be technically resectable, but the patient is unfit for a major surgical procedure due to accompanying illnesses, or in patients with severe liver cirrhosis, where a resection might not leave enough functional liver tissue behind (8). In addition, there is an increasing number of patients who will not agree to undergo a major liver resection, but ask for a less invasive alternative such as laparoscopic cryoablation. In our institution, we have treated 9 patients with solitary resectable tumors, who either were in a poor general condition or refused to undergo liver resection, with laparoscopic cryotherapy (Fig. 4 ).
Between January 1996 and September 2002, 77 patients underwent hepatic cryotherapy on 83 occasions (six repeat cryotherapies) in our department. Fifty-five of these patients had cryotherapy (25 of these in combination with liver resection) for colorectal liver metastases. Six patients had hepatoma, four patients had metastases from breast cancer, four metastases from gastric cancer and eight metastases from other primaries. The patient-, tumor-and operative details were recorded prospectively. Our earlier experience with the first patients in our series and the results of patients with colorectal primaries have been previously reported (21, 22) .
The median age of the 77 patients treated in our series was 65 years with a range of 37-78 years. Forty-four patients were male. Thirty-nine patients have been treated with systemic chemotherapy before cryotherapy and 21 have had a preceding liver resection and intrahepatic recurrence. The mean diameter of the liver lesions was 3.6cm with a range of 1.5-11cm. The mean number of lesions was 2.5 with a range of 1-10 lesions. Forty patients had only cryotherapy and 37 had liver resection in combination with cryotherapy.
Preoperative staging included abdominal ultrasound and abdominal computed tomography (CT), chest X-ray, serum analysis of tumor markers, liver function tests and colonoscopy. Recently, we have increasingly used magnetic resonance imaging (MRI) of the liver, particularly for better assessment of the tissue changes following cryotherapy.
Technique
Cryotherapy was usually performed via a bilateral subcostal incision. Before treatment inspection and palpation of the abdominal cavity, the liver and the hilar region, including intraoperative ultrasound and frozen section of suspicious lesions, was performed to exclude additional disease. Biopsies were taken from lesions treated by cryosurgery before treatment. For cryotherapy, we have initially used a CMS AccuProbe 450-System with single-use cryoprobes with an isolated shaft and a diameter of 3 or 8 millimeters at the tip. Probe tip temperatures reach around -180º C with this device. For the last three years, we have preferably used the Erbokryo CS-6 cryosystem (Erbe, Elektromedizin GmbH, Tübingen, Germany) with 3.6mm probes, which also cool down to around -180º C at the tip. Only the probe-tips are cooled, allowing the treatment of central lesions deep within the liver parenchyma without freezing the liver surface.
The probe insertion and the freezing process were controlled by intraoperative ultrasound. The ultrasonic characteristics of frozen liver have been first described in vitro (23) and later in vivo in a dog model (24, 25) . The iceball appears as a dense black (hypoechoic) area with a white (hyperechoic) rim, representing complete reflection of the ultrasound waves at the solidification interface between frozen and unfrozen tissue with posterior acoustic shadowing, which allows precise monitoring of the growth of the iceball using real time ultrasound (23, 24, 26, 27) . At full thaw, the previously frozen region appears hypoechoic compared to the surrounding liver, allowing precisely assessment of treated and untreated areas (23, 24) . The estimated sizes of the iceballs as measured by intraoperative ultrasound correlate closely with the size of the macroscopically visible "cryolesion" in the liver specimen (24, 26, 28) . We have not used thermocouples to monitor the achieved temperature at the tumor margin (8, 26).
All tumors were frozen with a surrounding margin of at least 1cm of normal tissue and the freezing process was continued at least 15 minutes. After a passive thaw of the iceball, we have used a second freeze cycle to optimize tumor destruction (29). In nine patients, cryotherapy was performed laparoscopically.
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Figure 2: a) CT-scan of a patient with bilobar liver metastases in liver segments 1, 4, 5, 7/8, 4 and segments 2/3. We have performed an extended right hemihepatectomy (resection of segments 4-8 and segment 1 (caudate lobe)) with cryotherapy of the remaining metastasis in the liver remnant (segments 2/3). b) The specimen of the liver resection (segment 4-8 and 1). c) Postoperative MRI-scan showing the cryonecrosis in segments 2/3 prior to discharge of the patient from hospital.
Figure 3: a)
CT-scan of a patient with two recurrent liver metastases from colorectal cancer in liver segments 7 and 8 (between right hepatic vein and inferior vena cava). Thirteen months earlier, this patient underwent a left hemihepatectomy with resection of the left and middle hepatic vein and three peripheral resections of the right lobe of the liver for a total of 5 metastases. Due to the high risk of damaging the only remaining hepatic vein in the attempt to resect the metastasis in segment 8 we have only resected the metastasis in segment 7 and treated the metastasis in segment 8 with cryotherapy. b/c) The postoperative CT-scan prior to discharge shows a small fluid collection at the resection edge in segment 7 and the cryonecrosis in segment 8. The right hepatic vein was patent with normal blood flow. d) The CT-scan 2 years postoperatively shows no signs of recurrence and the zone of cryonecrosis is no longer visible.
Figure 4: a)
Preoperative CT-scan of a patient with a solitary liver metastasis of a spindle cell tumor of the rectum. The patient declined to undergo resection; therefore, we treated the metastasis with laparoscopic cryotherapy. b) The MRI prior to discharge of the patient from hospital shows the zone of cryonecrosis in the treated area. c) The CT-scan 6 months postoperatively shows the shrinking scar at the cryosite with the typical "golf ball in the sand" appearance.
Postoperatively most patients were monitored on the intensive care unit, usually for 24 hours. Prior to discharge, a CTscan or MRI of the liver was performed.
Follow-up and Statistics
Patients were followed up until September 2002 or death. Mean follow-up was 24 months (1-73). Patients had regular 3 month follow-up investigations for local recurrence or hepatic recurrence at other locations and extrahepatic recurrence. In the first two postoperative years, abdominal ultrasound, clinical investigation and tumor markers were controlled three-monthly. Chest x-ray and abdominal CT were performed six-monthly, or if recurrence was suspected by the results of abdominal ultrasound, clinical investigation, or tumor markers. Suspected recurrences were confirmed by biopsy if in doubt. After two years follow-up, investigations were made every six months and every twelve months after four years. Survival was calculated using the . The log-rank test (31) was used to test for differences between the two groups. A significant difference was assumed for p < 0.05. Statistical analysis was performed using SPSS for Windows, version 10.0.7.
Results
One patient (1.3%) with extended right hemihepatectomy and cryotherapy of additional lesions in the left lateral segments died in the postoperative period due to multi-organ failure. Sixteen of the remaining 76 patients developed complications in the postoperative period: hemorrhage (n=3); esophageal variceal hemorrhage (n=1); intraabdominal abscess (n=3); bilio-pulmonary fistula (n=1); wound infection (n=2); transient liver failure (n=2); pleural effusion (n=5); pneumonia (n=1); pulmonary embolus (n=1) ( Table I) .
Thirty-eight of the 55 patients with colorectal liver metastases had an elevated serum carcinoembryonic antigen (CEA)-level preoperatively. In 26 of these 38 patients (68%) it returned to the normal range following cryosurgery.
For all 77 patients, median survival was 28 months with a 3and 5-year-survival rate of 39% and 26%, respectively (Fig. 5) . For the 55 patients with colorectal liver metastases, median survival was 29 months with a 3-and 5-year-survival rate of 44% and 26%, respectively (Fig. 6 ).
The recurrence pattern was analyzed for patients with initially complete tumor treatment ("R0-situation"). A "R0 treatment" was assumed if all tumors treated by cryotherapy were completely frozen with a surrounding margin of 1cm normal liver tissue, as judged by the surgeon and in cases of additional resection, if this was histologically confirmed as resection with clear margins. A "R0-treatment" was possible in 65 of 77 patients. Of these 65 patients, 19 were diseasefree at a mean follow-up of 23 months. Nineteen developed hepatic recurrence only -in six of these involving the cryotreated site, 23 developed hepatic and extrahepatic recurrence -in seven of these involving the cryotreated site. Four developed extraheptic recurrence only. Local recurrence at the cryosite (in other words, treatment failure) was observed in 13 of 65 patients (20%).
Radicality of Treatment, Recurrence and CEA
In 26 of the 38 patients with colorectal liver metastases and an elevated serum carcinoembryonic antigen (CEA)-level preoperatively, it returned to the normal range postoperatively. Twenty-four of these 26 patients had a R0 procedure. Eighteen of these 24 developed recurrence (three of 18 at the cryotreated site). In 11 of 38 patients with preoperatively elevated CEA, it remained elevated postoperatively (in one patient, postoperative CEA was not measured). Seven of these 11 patients had a R0 procedure. Five of these seven developed recurrence (two of these seven at the cryotreated site).
Laparoscopic Cryotherapy
We have treated nine patients with solitary resectable tumors, who either were in a poor general condition or refused to undergo liver resection, with laparoscopic cryotherapy. Two had hepatoma, five colorectal metastases and two metastases from other primaries. The tumor diameters ranged from 2-6cm with a median of 3cm. The duration of the procedure ranged from 95 to 360 minutes with a median of 170 minutes. There was no perioperative morbidity or mortality observed. Complete tumor ablation was achieved in 8 of 9 patients. All five patients with colorectal metastases are alive at 20, 22, 27, 29, and 40 months postoperatively. Three of five are disease-free, one has developed a new liver metastasis and one has recurred at the cryosite and developed pulmonary metastases.
Discussion
During the last two decades cryotherapy of liver tumors has evolved from an experimental technique to a clinically widely applied method. The results of many investigators from different centers, including our own have shown that crytherapy of liver tumors is feasible and that it may be performed with a perioperative morbidity comparable to or even lower than observed for liver resection (Table II) (2, 6, 7, (46) (47) (48) . Survival results are promising in some series (Table II) and there is 5 year survival data in studies with more than 50 patients now available from three centers with 15, 19 an 26% of patients surviving 5 years following cryoablation (32, 39, current series) of colorectal liver metastases, which compares well with the results of even modern chemotherapy regimens (3-5). However, the results are not as good as survival data following liver resection with 5 year survival rates between 28% and 37% in large series, which may partly reflect patient selection (47, 48) . The slightly inferior results to liver resection may also be related to the problem of local treatment failure (local recurrence at the cryosite), which was observed in about 14-33% of patients in most series, but in up to 60% of patients in some series (Table II) .
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While cryotherapy is close to "minimally invasive" from its approach to the liver tumors as compared to liver resection, laparotomy is used in most cases to expose the liver, which makes hepatic cryotherapy a rather invasive procedure, requiring general anesthesia and a hospital stay of at least about one week or even considerably longer in some centers, including our own. This did not matter too much ten years ago, when cryotherapy compared well to liver resection regarding its invasiveness and a rather ineffective chemotherapy would have been the alternative for most patients. Today however, there are competing techniques for liver tumor ablation, such as radiofrequency ablation (RFA) or laser induced thermo therapy (LITT) (Table III) , which offer similar or even better results regarding local tumor control, comparable survival data and can be applied percutaneously under local anaesthesia.
Concluding form the above mentioned considerations, the following goals need to be achieved for hepatic cryoablation:
I)
Minimizing the trauma of the procedure II)
Minimizing local treatment failure III) Optimizing survival results
Minimizing the Trauma of Hepatic Cryotherapy
One way to reduce the trauma of hepatic cryotherapy for the patient is to minimize the incisional trauma. Avoiding a large bilateral subcostal incision may be achieved by laparoscopic cryotherapy, which still requires general anaesthesia, or by a percutaneous approach, which may be performed with local anaesthesia. Other fields of research include the reduction of local and systemic side effects of cryosurgery.
Laparoscopic Hepatic Cryotherapy
In addition to our clinical experience, there are several groups, who have reported the laparoscopic application of hepatic (Table IV) . From the existing data it may be concluded, that laparoscopic cryoablation can be performed with minimal morbidity and is effective. However, there are only a few patients with non-resectable metastases, who have been treated with laparoscopic cryotherapy yet. Most patients treated had superficial small lesions, which can be easily localized via laparoscopy. The development of laparoscopic ultrasound probes capable of three-dimensional imaging may facilitate the use of laparoscopic cryoablation for nonresectable lesions. In addition, advances have been made in the surgical techniques of laparoscopic liver resection (57-59). This may allow combined laparoscopic liver resection and cryotherapy for bilobar lesions in the near future.
Percutaneous Hepatic Cryotherapy
While laparoscopic cryotherapy requires general anaesthesia and several small incisions of 10-12mm, a percutaneous approach would only require minimal incisions of 2-3mm for the insertion of the probes and local anaesthesia of the skin and the peritoneum. Several groups have worked on the percutaneous approach for hepatic cryoablation.
One group has focussed on MRI (magnetic resonance imaging) -guided percutaneous cryotherapy. They have initially developed a MR compatible nitrogen cooled glass probe and evaluated this in pig liver and an in vivo rabbit model (60, 61) . While these investigations demonstrated that MR-guided cryoablation was feasible with this probe, the ablation areas were far too small for the clinical application. Later, the same group focused on an MR-compatible system using argon gas cooled probes. This system was evaluated in an in vivo pig liver model and it was shown that the technique is feasible, that the zone of necrosis correlates well with the lesions seen in MRI, and that there were no major bleeding complications (62). The same group has used this technique in 14 patients with unresectable liver tumors. However, they have only used it as a palliative procedure: in 9 of 13 patients at a mean follow-up of 4 months, a "control" of the lesions (complete ablation or no additional tumor growth) was achieved (63). There were two patients with post interventional hemorrhage in the early experience, of whom one needed to undergo surgery for control of the bleeding. Later, they used embolization of the tract of the cryoprobe with tissue glue and did not see any more significant hemorrhage (62). While this concept is interesting, it is limited by the inadequate size of the cryolesions, of only about 3.5cm in diameter, achieved with this system. This is clearly not suitable for the treatment of most patients, when a curative approach is the aim.
A different approach is the use of conventional cryoprobes, which are positioned percutaneously under CT-guidance. Lee et al. have demonstrated the feasibility of this approach, using argon gas cooled probes in a pig liver model and have
shown that the areas of necrosis produced closely correlated with the visualized area of freezing in CT (64). Another group have used liquid nitrogen cooled probes percutaneously under CT-guidance to treat 17 patients with colorectal liver metastases. They have performed the procedure under general anaesthesia and have used Gelfoam slurry to embolize the probe tract for the prevention of bleeding. There were no perioperative deaths and complications developed in 6 of 17 patients. Hemorrhage requiring laparotomy only occurred in one patient (65). There is no data given regarding survival or local tumor control and cryotherapy seems to have been used as a palliative procedure only. For percutaneous cryotherapy to establish itself as an alternative to percutaneous RFA or LITT, the technique needs to be developed in a way that allows application in local anaesthesia and a curative approach. So far, the reported results are very disappointing regarding local tumor control compared to laparoscopic or open cryoablation or compared to percutaneous RFA or LITT.
Local Side Effects of Hepatic Cryotherapy
The major local problems in hepatic cryotherapy are freezing injury to large vessels and especially bile ducts. The possibility of freezing close to large vessels without causing permanent damage, as opposed to bile ducts, which are damaged permanently if frozen has been shown more than 30 years ago (17). Especially liver tumors close to critical vascular structures are an important indication for cryotherapy ( Fig. 7) , since proximity of hepatic lesions to important major vessels, such as the inferior vena cava (IVC) or the hepatic veins is one of the possible criteria forbidding liver resection. It would be ideal if those lesions could be treated by cryotherapy. However, it has been argued that tumor areas immediately adjacent to large blood vessels might be subject to inadequate freezing, due to the heat sink effect of the flowing blood in the vessel (11, 29) . To overcome this problem, hepatic inflow occlusion or temporary occlusion of hepatic veins might be used to reduce blood flow (11). When the cryoprobe is placed immediately adjacent to the vessel, providing high cooling rates in this region, complete destruction of tumors abutting major vessels may be achieved (67). However, we have certainly experienced local recurrence of tumor close to large blood vessels following cryoablation.
In animal studies, it has been shown that large intrahepatic vessels (portal or hepatic vein branches) with a diameter of more than 5mm may be completely frozen without compromising vessel patency, even if all layers of the vessel showed infarction. The use of hepatic inflow occlusion had no significant impact on the histological changes of the blood vessels observed (68). In a porcine model, cryosurgery involving the inferior vena cava was investigated. At autopsy, transmural damage of the caval wall extending into the intimal layer was seen in 35% of lesions. However, all vessels were patent and there was no evidence of ruptures of the vessels, thrombosis, or pulmonary embolism (69). Even if growing vessels are frozen, as investigated in a juvenile rat model involving freezing of the aorta, vascular patency is maintained and animal growth and structural function is preserved, despite cellular injury and wall compression (70).
Lesions close to hilar structures, such as portal vein branches are always also in the proximity of major bile ducts, which may be damaged by the freezing process, resulting in bilomas or biliary fistulas (16) (17) (18) . While freezing injury to intrahepatic bile ducts is not often followed by serious morbidity (68), we have certainly seen major morbidity due to this problem (Fig. 8 ). An even greater problem is the treatment of tumors in the porta hepatis, where extrahepatic bile ducts are at risk of injury. While there are reports of animal models or even clinical application of bile duct warming devices allowing treatment of hilar tumors (71, 72) , this still remains difficult. A more reliable technique of bile duct protection would be of interest to allow treatment of tumors in this region. Figure 8: a/b ) Preoperative CT-scans of a patient with recurrent liver metastases from gastric cancer who recurred after the resection of the primary tumor and left lateral segmentectomy of the liver for metastases. He was presented with 3 new liver metastases in segment 7 (a) and segments 5 and 6 (b). Cryotherapy of all 3 metastases was performed. The MRI prior to discharge shows cryonecrosis at the treatment sites (c), with one of the treatment sites close to the diaphragm (d). Four weeks postoperatively, the patient presented with fever and cough with yellowish sputum. e) The CTscan at that time showed a small fluid collection around the cryolesion in segment 7. f/g) The chest x-ray showed a basal infiltrate of the right lung, as did the CT-scan of the chest. h) The hepatobida-scintigraphy showed a bilio-pulmonal fistula with a pooling of the marker around the cryoleison in segment 7 (+) and in the right lung (#). In the yellowish sputum, bilirubin was found. The patient underwent a second laparotomy with closure of the biliary fistula and suture of the diaphragm.
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Systemic Side Effects of Hepatic Cryotherapy
There is a rather specific complication of hepatic cryotherapy that is referred to as the cryoshock phenomenon. It is a syndrome of multiorgan failure, severe coagulopathy, and disseminated intravascular coagulation (DIC), very similar to septic shock, but without evidence of any systemic sepsis and was responsible for the death of two patients who had large central lesions frozen in the Pittsburgh series (10). In a survey about morbidity following cryotherapy, the phenomenon of cryoshock was observed in 1% of patients and was responsible for 18% of the total mortality. Six of 33 perioperative deaths were related to cryoshock (73).
The postoperative occurrence of some aspects of cryoshock is much more frequent than the full syndrome. In a study of 4 patients receiving hepatic cryotherapy in combination with intraoperative systemic chemotherapy one patient developed severe thrombocytopenia with a nadir of 43,000/mm 3 and acute respiratory distress syndrome without a detectable septic focus being present (74). Severe DIC necessitating repeated infusions of fresh frozen plasma (FFP), cryoprecipitate, platelets and tranexamic acid was observed in 2 out of 100 patients in another series (75). It was speculated that toxic substances deriving from necrotizing liver tissue might be related to those changes (33).
Recently, some research regarding the underlying pathophysiological mechanisms of cryoshock was published. In work on a rat model, we have shown that there was a significant release of tumor necrosis factor (TNF)-α and interleukin (IL)-6 following hepatic freezing, which was greatest following large volume freezing with double freeze thaw cycles. Postoperative serum cytokine levels were significantly associated with hepatocellular injury, as measured by postoperative serum AST concentrations. Severe hemoglobinuria and renal injury, as demonstrated by serum creatinine and glomerular neutrophil count, were observed and were greatest following large volume freezing with double freeze thaw cycles. From this we concluded that it is likely that the cryoshock phenomenon is another form of systemic inflammatory response syndrome and possibly mediated by cytokines released from the frozen liver tissue (76). In addition, we have shown that in patients undergoing cryosurgery alone or in combination with liver resection, the volume and duration of freezing were significantly associated with postoperative serum AST and plasma TNF-α and IL-6 levels at various postoperative times, suggesting that these mediators may be involved in the occurrence of cryoshock (77). Interestingly, another group has reported that the complication rate significantly increased when the extent of hepatic cryotherapy exceeded a total estimated area of 30cm 2 , as measured in the preoperative , which may be explained by the release of proinflammatory cytokines.
One group of researchers has intensely studied the acute lung injury following hepatic cryoablation. In a rat model, they found a systemic inflammation with activation of nuclear factor kappaB (NF-κB) and increased production of NF-κB dependent cytokines (79) as well as probable cytokine mediated severe lung injury (80) following cryoablation of 35% of the liver. These changes were not detectable following RFA of the same amount of liver tissue (81). In a sheep model of cryoablation of 35% of the liver volume, changes similar to those observed with endotoxin and other systemic inflammatory stimuli (early postoperative increases of mean pulmonary pressure and lung lymph-plasma protein clearance) were seen (82). They have also demonstrated evidence of multi-organ inflammation in response to 35% hepatic cryotherapy in BALB/c mice with early postoperative increased NF-κB activation and KC and Macrophage Inflammatory Protein-2 (MIP-2) levels as well as neutrophilic lung inflammation (83).
While there is increasing knowledge of the mechanisms of the systemic inflammation observed following hepatic cryoablation, there is not much information regarding possible ways to avoid this problem, apart from limiting the extent of cryoablation. Substances which may be able to block the systemic side effects of hepatic cryotherapy would be of interest as they would allow large volume cryotherapy in patients with multiple liver tumors.
Minimizing Local Treatment Failure Following Hepatic Cryoablation
We have seen local treatment failure (or local recurrence at the treated site) in 20% of patients following complete ablation as judged by the surgeon intraoperatively. In other centers, local recurrence was observed in about 14-33% of patients in most series, but in up to 60% of patients in some series (Table II) . Although in some cases, repeated cryoablation is possible (84) even at the previously treated site, the observed rates of local recurrence are highly unsatisfactory. In addition, competing local ablative techniques seem to offer better local tumor control in the hands of experienced therapists, with local recurrence rates of as low as 1.7% at 6 months following LITT or 3% following RFA (Table III) . In one study comparing RFA and cryotherapy of liver tumors, a much higher morbidity and local recurrence rates (41% and 14%, respectively) were observed following cryotherapy, as compared to RFA (3% and 2%, respectively) (51). It is evident that cryotherapy will lose importance in the treatment of liver tumors if local recurrence rates can not be reduced significantly.
However, in a study comparing local recurrence after treatment of liver tumors > 3cm in diameter the results of RFA with 38% were inferior to cryotherapy with 17% (44). Cryotherapy may be more effective in the treatment of larger lesions, as compared to RFA. However, manufacturers of RFA devices have rapidly developed new types of probes in the last few years, which may help to improve the results of RFA for larger lesions.
Clearly, one important factor in reducing local recurrence is the experience of the surgeon (21). Another important point is knowledge about the parameters needed for effective destruction of tissue by freezing (85). The critical factor which can be influenced most by the surgeon is the lowest temperature achieved in the target tissue. Therefore, it is crucial to know the temperature that is needed for the effective cryoablation of different cancerous tissues in liver in vivo under clinical conditions. There is little data available in this regard. The only paper investigating this problem for colorectal cancer in liver in vivo has used a rat model and defines a temperature of -38º C or lower as effective for tumor ablation (86). However, this study is limited by the small number of animals used, and it may well be that ineffective treatment in some tumors frozen to ≤-38º C may be observed with a greater number of animals treated. In addition, the thermosensitivity of human colorectal cancers may differ from rat colorectal cancers or may even differ between different human colorectal cancers (87). Clearly, more research in this area is needed to define the critical temperature for the effective ablation of different human tumors in liver in vivo.
When this goal is achieved, the surgeon would in addition need to know the exact temperature distribution within the iceball to allow the calculation of the needed probe(s) and the exact probe placement to achieve the necessary temperature at the whole area of the target lesion.
Different investigators have focused on this topic. Our own group has used an in vivo pig liver model to evaluate different freeze thaw cycles with 8mm liquid nitrogen cooled probes and to describe the temperature changes at different distances to the cryoprobe during freezing (88). Others have used magnetic resonance imaging (89, 90) or estimated 3D temperature maps (91) to get insight in the temperature distribution within the iceball during cryosurgery. While the estimation of temperature distribution using one probe is rather simple, it becomes much more complicated when multiple probes are used to treat one tumor, or the effect of blood vessels within the treatment zone is considered (92). From the results of these studies, it becomes evident that for the effective treatment, especially of larger lesions (> 3cm) where the recurrence rate is even more unsatisfying (93), exact preoperative planning of cryoablation is crucial. The clinical practice of just freezing the tumor with a 1cm rim of surrounding liver tissue under ultrasound control will result in local recurrence in a significant proportion of patients with larger tumors or tumors close to major blood vessels.
Even with thorough preoperative planning, the results of hepatic cryotherapy will depend on the experience of the surgeon (or radiologist) in the use of intraoperative ultrasound (94). It is likely that probe placement and monitoring of the freezing process may be further improved with the use of three dimensional ultrasound. In one clinical study of focal liver ablation, the additional use of three-dimensional ultrasound caused the operator to readjust the number or position of probes in 45% of procedures (95).
Postoperatively, the use of Fluorine-18-Deoxyglucose Positron Emission Tomography (FDG-PET) may be valuable in detecting incomplete treatment. In one study, all local recurrences following local ablation (RFA or cryotherapy) of liver metastases were predicted by FDG-PET 3 weeks postoperatively (96). This may allow early retreatment of incompletely ablated lesions.
Optimizing Survival Results Following Hepatic Cryoablation
Certainly, complete tumor destruction is crucial to achieve good survival results. However, the magnitude of patients will develop tumor recurrence distant to the treatment site within or outside the liver (93). The recurrence pattern following cryotherapy is indeed very similar to patients following liver resection (47). Therefore, strategies to improve survival results are needed.
One possibility is to select patients who will undergo this treatment very carefully, using the available data regarding prognostic factors (13, 39, 97) . In one study where only patients with up to three small metastases were treated, survival results were excellent (14). However, most patients with up to three small lesions will be candidates for liver resection, and such strict selection will exclude most patients with non-resectable disease from cryosurgical treatment. There are certainly many patients with more than three metastases or larger lesions who still may benefit from cryotherapy (13), even if their prognosis may be impaired.
Another approach is to offer additional treatment modalities to patients undergoing hepatic cryoablation. Adjuvant systemic (33) or regional (13) chemotherapy following cryoablation has been used to improve survival results for patients with colorectal cancer liver metastases. The combination of neo-adjuvant systemic chemotherapy with 5-FU and folinic acid either alone or in combination with oxaliplatin for 131 patients with initially unresectable colorectal cancer liver metastases, followed by liver resection (n=33) or cryotherapy and liver resection (n=24) lead to 4-year survival rates of 37% after resection and 36% after resection and cryotherapy (43). In a non-randomized case control study, the results of cryosurgery (±liver resection, n=114) or cryosurgery (±liver resection, n=71) followed by regional FUDR and systemic irinotecan for unresectable colorectal cancer liver metastases were compared: Patients receiving adjuvant chemotherapy had significantly fewer recurrences at a median follow-up of 20 months. In addition, median survival rates and 2-year survival rates were improved with adjuvant therapy (20 vs. 30.6 months and 35% vs. 75%, respectively) (98).
With improving results of palliative systemic chemotherapy, especially for colorectal cancer during the last years (3-5, 99, 100), it is likely that adjuvant or neo-adjuvant treatment protocols will be developed that may improve the survival results of liver resection or any efficient local ablative technique for colorectal liver metastases. It is crucial that patients are entered in clinical trials investigating these treatments.
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